肿瘤免疫检查点抑制剂及其联合疗法的研究进展

肿瘤免疫检查点抑制剂及其联合疗法的研究进展(8)

http://www.100md.com 2020年4月1日《中国药房》 20207

     [54] Bristol-myers Squibb. Aninvestigational immuno-therapy study to assess the safety，tolerability and effectiveness of anti-LAG-3 with and without Anti-PD-1 in the treatment of solid tumors[EB/OL].[2020-01-18]. https：//clinicaltrials.gov/ct2/show/NCT01968109？cond=NCT01968109& draw=2&rank=1.

    [55] Regeneron Pharmaceutical. Study of REGN3767 (Anti- LAG-3) with or without REGN2810 (Anti-PD1) in advanced cancers[EB/OL].[2020-01-18]. https：//clinicaltrials.gov/ct2/show/NCT03005782？cond=NCT03005782& draw=2&rank=1.

    [56] LIZOTTE PH ......

上一页第 1 2 3 4 5 6 7 8 页

百拇医药网 http://www.100md.com/html/paper/1001-0408/2020/07/24-7.htm

您现在查看是摘要页，全文长 2840 字符。